Indoleamine 2,3-dioxygenase (IDO): Only an enzyme or a checkpoint controller?
Tryptophan (Trp) is one of the important essential amino acids and Kynurenine pathway (KP) is the first and rate limiting step of degrading Trp to active metabolites. Recent studies showed that KP metabolites have antimicrobial and immunosuppressive roles. The main controller enzyme of this pathway...
| Published in: | Journal of Oncological Sciences |
|---|---|
| Main Authors: | Cemil Bilir, M.D., Can Sarisozen, PhD |
| Format: | Article |
| Language: | English |
| Published: |
Turkish Society of Oncology
2017-07-01
|
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2452336417300201 |
Similar Items
TRYPTOPHAN AND INDOLEAMINE-2,3-DIOXYGENASE (IDO) IN PATHOGENESIS OF IMMUNOSUPPRESSIVE CLINICAL CONDITIONS
by: V. A. Kozlov, et al.
Published: (2017-07-01)
by: V. A. Kozlov, et al.
Published: (2017-07-01)
Comprehensive behavioral analysis of indoleamine 2,3‐dioxygenase knockout mice
by: Nao Hirata, et al.
Published: (2018-09-01)
by: Nao Hirata, et al.
Published: (2018-09-01)
Indoleamine 2,3-Dioxygenase (IDO) Activity: A Perspective Biomarker for Laboratory Determination in Tumor Immunotherapy
by: Pengbo Yang, et al.
Published: (2023-07-01)
by: Pengbo Yang, et al.
Published: (2023-07-01)
The Relationships among Tryptophan, Kynurenine, Indoleamine 2,3-Dioxygenase, Depression, and Neuropsychological Performance
by: Knut A. Hestad, et al.
Published: (2017-10-01)
by: Knut A. Hestad, et al.
Published: (2017-10-01)
The Two Sides of Indoleamine 2,3-Dioxygenase 2 (IDO2)
by: Chiara Suvieri, et al.
Published: (2024-11-01)
by: Chiara Suvieri, et al.
Published: (2024-11-01)
Indoleamine 2,3-dioxygenase 1 as a metabolic switch in sepsis-induced immunosuppression: transcriptomic validation and therapeutic inhibition by novel quinoline derivativesNCBI-GEO
by: Deepthi Sreepathi, et al.
Published: (2026-01-01)
by: Deepthi Sreepathi, et al.
Published: (2026-01-01)
Significance of Indoleamine 2,3-Dioxygenase Expression in the Immunological Response of Kidney Graft Recipients
by: Krzysztof Wiśnicki, et al.
Published: (2022-09-01)
by: Krzysztof Wiśnicki, et al.
Published: (2022-09-01)
Indoleamine 2,3-dioxygenase 1 expression predicts cholangiocarcinoma patient survival
by: Mallika Naeklang, et al.
Published: (2026-06-01)
by: Mallika Naeklang, et al.
Published: (2026-06-01)
Increased Indoleamine 2,3-Dioxygenase 1 (IDO-1) Activity and Inflammatory Responses during Chikungunya Virus Infection
by: Thiara Manuele Alves de Souza, et al.
Published: (2022-04-01)
by: Thiara Manuele Alves de Souza, et al.
Published: (2022-04-01)
Targeting Indoleamine 2,3-Dioxygenase in Cancer Models Using the Novel Small Molecule Inhibitor NTRC 3883-0
by: Yvonne Grobben, et al.
Published: (2021-01-01)
by: Yvonne Grobben, et al.
Published: (2021-01-01)
Indoleamine 2,3 dioxygenase (IDO) level as a marker for significant coronary artery disease
by: Nattawut Wongpraparut, et al.
Published: (2021-07-01)
by: Nattawut Wongpraparut, et al.
Published: (2021-07-01)
Regulation of the Immune Checkpoint Indoleamine 2,3-Dioxygenase Expression by Epstein–Barr Virus
by: Leila Sawada, et al.
Published: (2021-11-01)
by: Leila Sawada, et al.
Published: (2021-11-01)
Association of Indoleamine 2,3-Dioxygenase (IDO) Activity with Outcome after Cardiac Surgery in Adult Patients
by: Andrea Stieger, et al.
Published: (2024-06-01)
by: Andrea Stieger, et al.
Published: (2024-06-01)
Indoleamine 2,3- Dioxygenase: A Novel Immunotherapeutic Target for Osteosarcoma
by: Asim Farooq, et al.
Published: (2022-09-01)
by: Asim Farooq, et al.
Published: (2022-09-01)
Progesterone decreased indoleamine 2,3-dioxygenase 1(IDO1) expression in early pregnancy chorionic villi and decidua
by: Minyan Yang, et al.
Published: (2021-04-01)
by: Minyan Yang, et al.
Published: (2021-04-01)
Influence of Indoleamine-2,3-Dioxygenase and Its Metabolite Kynurenine on γδ T Cell Cytotoxicity against Ductal Pancreatic Adenocarcinoma Cells
by: Hannah Jonescheit, et al.
Published: (2020-05-01)
by: Hannah Jonescheit, et al.
Published: (2020-05-01)
Indoleamine 2,3-dioxygenase expression in patients with allergic rhinitis: a case-control study
by: Luukkainen Annika, et al.
Published: (2011-12-01)
by: Luukkainen Annika, et al.
Published: (2011-12-01)
Discovery of Indoleamine 2,3-Dioxygenase 1 (IDO-1) Inhibitors Based on Ortho-Naphthaquinone-Containing Natural Product
by: Hongchuan Zhao, et al.
Published: (2019-03-01)
by: Hongchuan Zhao, et al.
Published: (2019-03-01)
An Expanded Neuroimmunomodulation Axis: sCD83-Indoleamine 2,3-Dioxygenase—Kynurenine Pathway and Updates of Kynurenine Pathway in Neurologic Diseases
by: Li Bo, et al.
Published: (2018-06-01)
by: Li Bo, et al.
Published: (2018-06-01)
Indoleamine 2,3-Dioxygenase Is Involved in Interferon Gamma’s Anti-BKPyV Activity in Renal Cells
by: Tony Fiore, et al.
Published: (2020-08-01)
by: Tony Fiore, et al.
Published: (2020-08-01)
Research progress of indoleamine 2,3-dioxygenase 1 in gastric cancer
by: Pei Xiaxia, et al.
Published: (2023-03-01)
by: Pei Xiaxia, et al.
Published: (2023-03-01)
Kynurenines as a Novel Target for the Treatment of Inflammatory Disorders
by: Adrian Mor, et al.
Published: (2024-07-01)
by: Adrian Mor, et al.
Published: (2024-07-01)
IDO Expression in Cancer: Different Compartment, Different Functionality?
by: Annabel Meireson, et al.
Published: (2020-09-01)
by: Annabel Meireson, et al.
Published: (2020-09-01)
Indoleamine 2,3-Dioxygenase as a Therapeutic Target for Alzheimer’s Disease and Geriatric Depression
by: Karl Savonije, et al.
Published: (2023-05-01)
by: Karl Savonije, et al.
Published: (2023-05-01)
Discovery of cyanopyridine scaffold as novel indoleamine-2,3-dioxygenase 1 (IDO1) inhibitors through virtual screening and preliminary hit optimisation
by: Xi Xu, et al.
Published: (2019-01-01)
by: Xi Xu, et al.
Published: (2019-01-01)
What May Constrain the Success of Indoleamine 2,3-Dioxygenase 1 Inhibitors in Cancer Immunotherapy?
by: Theodoros Eleftheriadis
Published: (2018-08-01)
by: Theodoros Eleftheriadis
Published: (2018-08-01)
The Role of Indoleamine-2,3-Dioxygenase in Cancer Development, Diagnostics, and Therapy
by: Lilla Hornyák, et al.
Published: (2018-01-01)
by: Lilla Hornyák, et al.
Published: (2018-01-01)
DUAL INHIBITORS OF INDOLEAMINE-2,3-DIOXYGENASE (IDO) AND TRYPTOPHAN-2,3-DIOXYGENASE (TDO) AS ANTI-TUMOR IMMUNE MODULATORS
by: Mostafa Abouzeid, et al.
Published: (2024-03-01)
by: Mostafa Abouzeid, et al.
Published: (2024-03-01)
Inhibitory effect of human indoleamine 2,3-dioxygenase 1 (hIDO1) by kazinols of 1,3-diphenylpropane derivatives
by: Taehoon Oh, et al.
Published: (2024-09-01)
by: Taehoon Oh, et al.
Published: (2024-09-01)
Kynurenines as a Novel Target for the Treatment of Malignancies
by: Adrian Mor, et al.
Published: (2021-06-01)
by: Adrian Mor, et al.
Published: (2021-06-01)
First-in-Class, Thiosemicarbazide-Based, Dual Inhibitors of Human DNA Topoisomerase IIα and Indoleamine-2,3-Dioxygenase 1 (IDO-1) with Strong Anticancer Properties
by: Barbara Kaproń, et al.
Published: (2022-11-01)
by: Barbara Kaproń, et al.
Published: (2022-11-01)
IDO-Mediated Immune and Metabolic Dysregulation in Schwann Cells Exposed to <i>Mycobacterium leprae</i>
by: Atta Ur Rahman, et al.
Published: (2025-10-01)
by: Atta Ur Rahman, et al.
Published: (2025-10-01)
Indoleamine 2,3‐dioxygenase gene expression and kynurenine to tryptophan ratio correlation with nasopharyngeal carcinoma progression and survival
by: Sameh Souissi, et al.
Published: (2022-09-01)
by: Sameh Souissi, et al.
Published: (2022-09-01)
Contribution of indoleamine 2,3-dioxygenase in preeclampsia
by: Mona F.M El-Karn, et al.
Published: (2016-01-01)
by: Mona F.M El-Karn, et al.
Published: (2016-01-01)
Single Nucleotide Polymorphisms of Indoleamine 2,3-Dioxygenase 1 Influenced the Age Onset of Parkinson's Disease
by: Nóra Török, et al.
Published: (2022-09-01)
by: Nóra Török, et al.
Published: (2022-09-01)
Immunomodulatory Factors in Primary Endometrial Cell Cultures Isolated from Cancer and Noncancerous Human Tissue–Focus on RAGE and IDO1
by: Joanna Tkaczuk-Włach, et al.
Published: (2021-04-01)
by: Joanna Tkaczuk-Włach, et al.
Published: (2021-04-01)
Expression of Indoleamine 2,3-Dioxygenase Induced by IFN-γ and TNF-α as Potential Biomarker of Prostate Cancer Progression
by: Irina Banzola, et al.
Published: (2018-05-01)
by: Irina Banzola, et al.
Published: (2018-05-01)
Involvement of the tryptophan-kynurenine pathway in the pathogenesis of autoimmune diseases
by: A-Yuan Chen, et al.
Published: (2025-10-01)
by: A-Yuan Chen, et al.
Published: (2025-10-01)
Local Inhibition of Indoleamine 2,3-Dioxygenase Mitigates Renal Fibrosis
by: Camilla Grønkjær Jensen, et al.
Published: (2021-07-01)
by: Camilla Grønkjær Jensen, et al.
Published: (2021-07-01)
Serum indoleamine 2,3-dioxygenase level and diagnostic value in patients with rosacea
by: Merve Sena Odabasi, et al.
Published: (2023-01-01)
by: Merve Sena Odabasi, et al.
Published: (2023-01-01)
Similar Items
-
TRYPTOPHAN AND INDOLEAMINE-2,3-DIOXYGENASE (IDO) IN PATHOGENESIS OF IMMUNOSUPPRESSIVE CLINICAL CONDITIONS
by: V. A. Kozlov, et al.
Published: (2017-07-01) -
Comprehensive behavioral analysis of indoleamine 2,3‐dioxygenase knockout mice
by: Nao Hirata, et al.
Published: (2018-09-01) -
Indoleamine 2,3-Dioxygenase (IDO) Activity: A Perspective Biomarker for Laboratory Determination in Tumor Immunotherapy
by: Pengbo Yang, et al.
Published: (2023-07-01) -
The Relationships among Tryptophan, Kynurenine, Indoleamine 2,3-Dioxygenase, Depression, and Neuropsychological Performance
by: Knut A. Hestad, et al.
Published: (2017-10-01) -
The Two Sides of Indoleamine 2,3-Dioxygenase 2 (IDO2)
by: Chiara Suvieri, et al.
Published: (2024-11-01)
